Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 11, 2026

Adobe Reports Record Q2 Results

View original at finance.yahoo.com
Adobe Reports Record Q2 Results Adobe Raises FY26 Total Revenue and Non-GAAP EPS Targets AI-first ARR triples year over year and exceeds $500 million SAN JOSE, Calif., June 11, 2026--(BUSINESS WIRE)--Adobe (Nasdaq:ADBE), the global technology leader that unleashes creativity and productivity for individuals and busines…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FY26 financial targets factor in the acquisition of Semrush Holdings, Inc. and assume current macroeconomic conditions.

    60% confidence

  • AI-first ARR tripled year over year and exceeded $500 million.

    60% confidence

  • Adobe delivered record revenue of $6.62 billion in Q2 reflecting strong AI-driven demand across customer groups and is raising full-year fiscal 2026 revenue and non-GAAP EPS targets.

    60% confidence

  • Q2 FY2026 GAAP results reflect a $0.17 per share non-cash goodwill impairment charge related to the Publishing & Advertising reporting unit.

    60% confidence

  • Adobe is bringing AI products to consumers, business professionals, creators, and marketers to deliver on its mission to Empower Everyone to Create.

    60% confidence

Data points we hold from this source

Adobe Inc. · backlog27.10 USD
Adobe Inc. · margin2.24 USD
Adobe Inc. · eps4.25 USD
Adobe Inc. · cash2.17 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com